Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
63
datasets available to search
ShareScore release 0.7.1
Dataset results
63 results for “cost-effectiveness analysis”
Data and code from: Cost-effectiveness Analysis of Alternative Infant and Neonatal Rotavirus Vaccination Schedules in Malawi
Open the record for dataset details and reuse information.
An Empirical Analysis of Amazon EC2 Spot Instance Features Affecting Cost-effective Resource Procurement
<p>This repository contains code and data for the paper "An Empirical Analysis of Amazon EC2 Spot Instance Features Affecting Cost-effective Resource Procurement", by Cheng Wang, Qianlin Liang and Bhuvan Urgaonkar.</p>
Performance Measurement Dataset of the HPC Benchmarks FASTEST, Kripke, and RELeARN for Cost-Effective Modeling Analysis with Extra-P
<p>Performance Measurement Dataset of the HPC Benchmarks FASTEST, Kripke, RELeARN for Scalability Studies with Extra-P. This data was used to analyze cost-effective modeling approaches presented in the IPDPS 2020 paper "Learning Cost-Effective Sampling Strategies for Empirical Performance Modeling".</p>
Data and codes for "The impact, costs, and cost-effectiveness of tuberculosis outbreak investigations in the United States: a model-based analysis"
<p>Data and codes for the manuscript entitled:</p> <p>"<strong>The impact, costs, and cost-effectiveness of tuberculosis outbreak investigations in the United States: a model-based analysis"</strong></p> <p> </p> <p><strong>Please see Readme.txt for details</strong></p>
Data from: Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): a randomized trial and cost-effectiveness analysis
<p>Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of TB. We investigated costs and yield from systematic HIV-TB screening, including computer-aided digital chest X-ray (DCXR-CAD). Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of TB. We investigated costs and yield from systematic HIV-TB screening, including computer-aided digital chest X-ray (DCXR-CAD).</p> <p>In this open, three-arm randomised trial, adults (≥18 years) with cough attending acute primary services in Malawi were randomised (1:1:1) to standard-of-care (SOC); oral HIV testing (HIV screening) and linkage to care; or HIV testing and linkage to care plus DCXR-CAD with sputum Xpert for high CAD4TBv5 scores (HIV-TB screening). Participants and study staff were not blinded to intervention allocation, but investigator blinding was maintained until final analysis. The primary outcome was time to TB treatment. Secondary outcomes included proportion with same-day TB treatment; prevalence of undiagnosed/untreated bacteriologically-confirmed TB on day 56; and undiagnosed/untreated HIV. Analysis was done on an intention to treat basis. Cost-effectiveness analysis used a health-provider perspective. Between 15/11/2018-27/11/2019, 8236 were screened for eligibility, with 473, 492, and 497 randomly allocated to SOC, HIV, and HIV-TB screening arms; 53 (11%), 52 (9%), and 47 (9%) were lost to follow-up, respectively. At 56 days, TB treatment had been started in 5 (1.1%) SOC, 8 (1.6%) HIV-screening, and 15 (3.0%) HIV-TB screening participants. Median (IQR) time to TB treatment was 11 (6.5-38), 6 (1-22) and 1 (0-3) days (hazard ratio for HIV-TB vs. SOC: 2.86, 1.04-7.87), with same-day treatment of 0/5 (0%) SOC, 1/8 (12.5%) HIV, and 6/15 (40.0%) HIV-TB screening arm TB patients (p=0.03). At day 56, 2 SOC (0.5%), 4 HIV (1.0%), and 2 HIV-TB (0.5%) participants had undiagnosed microbiologically-confirmed TB. HIV screening reduced the proportion with undiagnosed or untreated HIV from 10 (2.7%) in the SOC arm to 2 (0.5%) in the HIV-screening arm (risk ratio [RR]: 0.18, 0.04-0.83), and 1 (0.2%) in the HIV-TB screening arm (RR: 0.09, 0.01-0.71). Incremental costs were US$3.58 and US$19.92 per participant screened for HIV and HIV-TB; the probability of cost-effectiveness at a US$1200/quality-adjusted life-year (QALY) threshold were 83.9% and 0%. Main limitations were the lower than anticipated prevalence of tuberculosis and short participant follow-up period; cost and quality of life benefits of this screening approach may accrue over a longer time horizon.</p> <p>DCXR-CAD with universal HIV screening significantly increased the timeliness and completeness of HIV and TB diagnosis. If implemented at scale this has potential to rapidly and efficiently improve TB and HIV diagnosis and treatment.</p>
Calcium fortification of water during pregnancy for the prevention of preeclampsia in a low-income setting: a cost-effectiveness analysis
<p>This database contains the model and the parameters of the study. It's is important to highlight that this is the first version of the model, and thus modifications are forthcoming. With the current database, the abstract is the following:</p> <p>Fortification of water with calcium during pregnancy is proposed as a suitable and promising intervention to increase calcium intake and prevent preeclampsia and eclampsia (PE/E). However, the evidence of the cost-effectiveness of this type of intervention is scarce. We conducted a model-based cost-effectiveness analysis to estimate the incremental cost-effectiveness ratio (ICER) of calcium pills and bottled water fortified with calcium, compared to the standard of care (defined as the use of MgSO4 as the standard treatment for PE/E), in the context of Nepal. Outcome measures were years of life gained (YLG) by mothers and newborns and healthcare costs. We considered a lifetime time horizon and health benefits were discounted at 3%. The cost-effectiveness threshold was set at the 2019 Nepal gross domestic product per capita (USD 1071). For calcium pills versus standard of care, ICER was USD 63 per YLG. By switching from calcium pills to bottled water fortified with calcium, the resulting ICER was USD 1702 per YLG. In conclusion, the bottle of water fortified with calcium was found not cost-effective at the defined threshold for Nepal. Complementary economic evidence adapted to other low-and middle income contexts is required to guide novel preventive interventions to improve maternal and child health based on the efficiency principle</p>
Cognitive development among children in a low-income setting: cost-effectiveness analysis of a maternal nutrition education intervention in rural Uganda
<p><span>Inadequate nutrition and insufficient stimulation in early childhood can lead to long-term deficits in cognitive and social development. Evidence for policy and decision-making regarding the cost of delivering nutrition education is lacking in low and middle-income countries (LMIC). In rural Uganda, we conducted a cluster-randomized controlled trial (RCT) examining the effect of a maternal nutrition education intervention on developmental outcomes among children aged 6–8 months. This intervention led to significantly improved cognitive scores when the children reached the age of 20–24 months. When considering the potential for this intervention's future implementation, the desired effects should be weighed against the increased costs.</span><span> This study therefore aimed to assess the cost-effectiveness of this education intervention compared with current practice.</span><span> Health outcome data were based on the RCT. Cost data were collected via interviews with researchers involved in processing the intervention. This study considered a healthcare provider perspective for an 18-month time horizon.</span><span> The control group was considered as the current practice for the future large-scale implementation of this intervention. </span><span>A cost-effectiveness analysis was performed, including calculations of incremental cost-effectiveness ratios (ICERs). In addition, uncertainty in the results was characterized using one-way and probabilistic sensitivity analyses. The ICER for the education intervention compared with current practice was USD ($) 16.50 per cognitive composite score gained, with an incremental cost of </span><span>$265.79 and an incremental cognitive composite score of 16.11. The sensitivity analyses indicated the robustness of these results. The ICER was sensitive to changes in cognitive composite score and the cost of personnel, but the education intervention can be considered cost-effective compared with the current practice. The outcome of this study, including the cost analysis, health outcome, cost-effectiveness, and sensitivity analysis, can be useful to inform policymakers and stakeholders about effective resource allocation processes in Uganda and possibly other LMIC.</span></p>
Cognitive development among children in a low-income setting: cost-effectiveness analysis of a maternal nutrition education intervention in rural Uganda
Open the record for dataset details and reuse information.
Decision analysis rooted in Indigenous and Western scientific knowledge identifies cost-effective strategies for managing hyperabundant deer to restore keystone places
Open the record for dataset details and reuse information.
Data from: Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): a randomized trial and cost-effectiveness analysis
Open the record for dataset details and reuse information.
Half-Dose Fulvestrant plus Anastrozole as a First-Line Treatment for Hormone Receptor-Positive Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Abstract Objective The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC[HR+]). The objective of this study was to evaluate the cost-effectiveness of F&A in the first-line treatment for PMW-MBC(HR+) in China. Design We constructed a Markov model over a life-time horizon. The clinical outcomes and utility data were obtained from published literature. Cost data were obtained from official Chinese websites. Sensitivity analyses were performed to test result uncertainty. Setting Chinese health care system perspective. Population A hypothetical cohort of adult patients presenting with PMW-MBC(HR+). Interventions F&A compared with full-dose FUL and ANA monotherapy. Main outcome measures The main outcome of this study was the incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALY). Results ANA was estimated to have the lowest cost and minimum life years (LYs). The ICER of F&A versus ANA was $15,665.891/QALY with incremental cost and QALY of $12,401.120 and 0.792, respectively, which was less than the willingness-to-pay (WTP) of $29,383/QALY. Compared with F&A, FUL yielded a higher cost and a shorter lifetime; hence, it was identified as a dominated strategy. The univariate sensitivity analysis indicated the price of FUL was the most influential factor in our study. The probability that F&A was cost-effective at a threshold of $29,383/QALY in China was 86.5%. Conclusion F&A is a cost-effective alternative to FUL and ANA monotherapy for the first-line treatment of PMW-MBC(HR+) in China. F&A is a promising first-line treatment for PMW-MBC(HR+), and more research is needed to evaluate the economy of using F&A in other countries.
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for RAS wild-type metastatic colorectal cancer patients based on the TAILOR trial
<p><b>Objectives</b> Cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomized, multicentre, phase III trial. Nevertheless, the cost-effectiveness of these two regimens remains uncertain. The following study aims to determine whether cetuximab combined with FOLFOX-4 is a cost-effective strategy for specific RAS wt mCRC patients in China.</p> <p><b>Design</b> A combined decision tree and Markov model with three health states (stable, progressive and dead) was constructed to simulate a hypothetical cohort of patients with RAS wt mCRC. The health outcomes and utility scores were derived from the TAILOR trial and previously published sources, respectively. Costs were calculated with reference to the Chinese societal perspective. A lifetime horizon was used. Univariate and probabilistic sensitivity analyses were carried out to test the robustness of the model results.</p> <p><b>Participants</b> The included patients were newly diagnosed Chinese patients with fully RAS wt mCRC. <b>Interventions</b> Either cetuximab plus FOLFOX-4 or FOLFOX-4 alone as a first-line treatment.</p> <p><b>Main outcome measures</b> The primary outcomes are costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs).</p> <p><b>Results</b> Baseline analysis showed that the addition of cetuximab increased the QALYs by 0.383, while an increase of $62,947 was observed in relation to FOLFOX-4 chemotherapy. This led to an incremental cost-effectiveness ratio (ICER) of $164,044/QALY. Sensitivity analysis showed that across the wide variation in parameters, the ICER exceeded the willingness-to-pay threshold of $28,106/QALY, which was three times the per capita GDP in China.</p> <p><b>Conclusions</b> Despite the survival benefit, cetuximab combined with FOLFOX-4 is not a cost-effective treatment for the first line treatment of patients with RAS wt mCRC in China.</p>
A cost-effectiveness analysis of second-generation antihistamine 1 receptor blockers and Japanese kampo shoseiryuto for treatment of perennial allergic rhinitis in outpatient settings in Japan
<p><strong><span>Background: </span></strong><span>Perennial allergic rhinitis (PAR) is common in Japan. Second-generation antihistamines (SGAs) are used commonly </span><span>for its</span><span> treatment, but it remains unclear which SGA is the most cost-effective. Additionally, the pharmacoeconomics of Japanese kampo shoseiryuto, which has been traditionally prescribed to treat PAR in Japan, remain poorly understood.</span></p> <p><strong><span>Objectives: </span></strong><span>This study aimed to investigate the effectiveness of various SGAs and shoseiryuto for the treatment of PAR in Japanese outpatients, from the healthcare payer's perspective, using a base-case analysis.</span></p> <p><strong><span>Methods: </span></strong><span>The current study entailed identification of the most cost-effective of the six SGAs (</span><span>bepotastine 10 mg, cetirizine 10 mg, ebastine 10 mg, </span><span>epinastine 20</span><span> mg, loratadine 10 mg, and olopatadine 5 mg) and shoseiryuto, whose clinical effectiveness were evaluated using the overall improvement rate. </span><span>T</span><span>he time horizon</span><span> was 14 days. Costs were identified based on the Medical Fee Index in 2020.</span></p> <p><strong><span>Key findings: </span></strong><span>Overall, bepotastine 10 mg, cetirizine 10 mg, </span><span>ebastine </span><span>10 mg, and loratadine 10 mg were found to be cost-effective. Shoseiryuto was less cost-effective than ebastine 10 mg (dominated). Ebastine 10 mg was found to be the most cost-effective based on deterministic and probabilistic sensitivity analyses.</span></p> <p><strong><span>Conclusions: </span></strong><span>Ebastine 10 mg was found to be the most cost-effective treatment strategy for PAR among the agents evaluated in this study</span><span>. This insight might help </span><span>in creating an appropriate formulary for the treatment of PAR in hospitals and communities.</span></p>
Cost-Effectiveness Analysis of a Virtual Reality-Assisted Hypnotherapy Program on Quality of Life in Patients with Chronic Low Back Pain: a Multicenter, Randomized, Prospective, Comparative, Open-Labe
ClinicalTrials.gov study NCT06698354. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis
ClinicalTrials.gov study NCT01720238. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cost-effectiveness Analysis Between Biosynthetic and Biological Parietal Prostheses
ClinicalTrials.gov study NCT03590184. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules
ClinicalTrials.gov study NCT02398721. IPD Sharing: Not stated. Countries: 1. Publications: 13.
Mandibular Overdenture Retained by 1 or 2 Implants: a Cost-effectiveness Analysis
ClinicalTrials.gov study NCT03691285. IPD Sharing: NO. Countries: 1. Publications: 0.
Cost-effective Analysis of Two Approximation Devices in Closure of Gastrointestinal Defects
ClinicalTrials.gov study NCT05163665. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Evaluation and Cost-effectiveness Analysis of 3D Digital Surgery in Traumatology
ClinicalTrials.gov study NCT06603831. IPD Sharing: YES. Countries: 1. Publications: 22.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.